Genomic Analysis for the Detection of Bleeding and Thrombotic Disorders

Abstract

The development of high-throughput sequencing technologies has ushered in a new era of genomic testing in clinical medicine. This has greatly enhanced our diagnostic repertoire for hemostatic diseases particularly for milder or rarer bleeding disorders. New genetic causes for heritable platelet disorders have been discovered along with the recognition of clinical manifestations outside hemostasis, such as the association of leukemia with RUNX1 variation. Genome-wide association studies in heritable thrombophilia have demonstrated that some of the genetic variants that are commonly included in thrombophilia testing are of no clinical relevance, while uncovering new variants that should potentially be included. The implementation of new technology has necessitated far-reaching changes in clinical practice to deal with incidental findings, variants of uncertain significance, and genetic disease modifiers. Mild bleeding disorders that were previously considered to have a monogenic basis now appear to have an oligogenic etiology. To harness these advances in knowledge large databases have been developed to capture the new genomic information with phenotypic features on a population-wide scale. The use of this so-called “big data” requires new bioinformatics tools with the promise of delivering precision medicine in the foreseeable future. This review discusses the use of these technologies in clinical practice, the benefits of genomic testing, and some of the challenges associated with implementation.

Keywords

inherited bleeding disorders - heritable platelet disorders - heritable thrombophilia - genetic testing - genetic reporting - genetic interpretation - genomic analysis - big data - bioinformatics

Publication History

Article published online:
26 February 2021

• References

• 1 Lander ES, Linton LM, Birren B. et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409 (6822): 860-921
• 2 Albers CA, Paul DS, Schulze H. et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet 2012; 44 (04) 435-439 , S1–S2
• 3 Downes K, Megy K, Duarte D. et al; NIHR BioResource. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood 2019; 134 (23) 2082-2091
• 4 Leo VC, Morgan NV, Bem D. et al; UK GAPP Study Group. Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. J Thromb Haemost 2015; 13 (04) 643-650
• 5 Megy K, Downes K, Simeoni I. et al; Subcommittee on Genomics in Thrombosis and Hemostasis. Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: communication from the SSC of the ISTH. J Thromb Haemost 2019; 17 (08) 1253-1260
• 6 Mellars G, Gomez K. Mutation detection by Southern blotting. Methods Mol Biol 2011; 688: 281-291
• 7 Sellner LN, Taylor GR. MLPA and MAPH: new techniques for detection of gene deletions. Hum Mutat 2004; 23 (05) 413-419
• 8 Moreno-Cabrera JM, Del Valle J, Castellanos E. et al. Evaluation of CNV detection tools for NGS panel data in genetic diagnostics. Eur J Hum Genet 2020; 28 (12) 1645-1655
• 9 Quenez O, Cassinari K, Coutant S. et al; FREX Consortium. Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation. Eur J Hum Genet 2021; 29 (01) 99-109
• 10 Rossetti LC, Radic CP, Larripa IB, De Brasi CD. Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene. J Thromb Haemost 2008; 6 (05) 830-836
• 11 Lakich D, Kazazian Jr HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5 (03) 236-241
• 12 Zöller B, Ohlsson H, Sundquist J, Sundquist K. A sibling based design to quantify genetic and shared environmental effects of venous thromboembolism in Sweden. Thromb Res 2017; 149: 82-87
• 13 Klarin D, Emdin CA, Natarajan P, Conrad MF, Kathiresan S. INVENT Consortium. Genetic analysis of venous thromboembolism in UK Biobank identifies the ZFPM2 locus and implicates obesity as a causal risk factor. Circ Cardiovasc Genet 2017; 10 (02) 1-7
• 14 Trégouët D-A, Morange P-E. What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. Br J Haematol 2018; 180 (03) 335-345
• 15 Hickey SE, Curry CJ, Toriello HV. ACMG practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013; 15 (02) 153-156
• 16 Mills MC, Rahal C. A scientometric review of genome-wide association studies. Commun Biol 2019; 2 (01) 9
• 17 Bariana TK, Ouwehand WH, Guerrero JA, Gomez K. BRIDGE Bleeding, Thrombotic and Platelet Disorders and ThromboGenomics Consortia. Dawning of the age of genomics for platelet granule disorders: improving insight, diagnosis and management. Br J Haematol 2017; 176 (05) 705-720
• 18 Seri M, Cusano R, Gangarossa S. et al; The May-Heggllin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet 2000; 26 (01) 103-105
• 19 Bury L, Megy K, Stephens JC. et al. Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Hum Mutat 2020; 41 (01) 277-290
• 20 Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154 (02) 161-174
• 21 Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005; 3 (08) 1773-1782
• 22 Galera P, Dulau-Florea A, Calvo KR. Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia. Int J Lab Hematol 2019; 41 (Suppl. 01) 131-141
• 23 Rejtő J, Königsbrügge O, Grilz E. et al. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. J Thromb Haemost 2020; 18 (05) 1081-1086
• 24 de Vries P, Brown MR. Whole genome sequencing study of coagulation factor VIII and von Willebrand factor reveals new genetic associations. Res Pract Thromb Haemost 2020; 4 :Suppl 1: 4
• 25 Green RC, Berg JS, Grody WW. et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15 (07) 565-574
• 26 Matthijs G, Souche E, Alders M. et al; EuroGentest, European Society of Human Genetics. Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet 2016; 24 (01) 2-5
• 27 Vears DF, Sénécal K, Clarke AJ. et al. Points to consider for laboratories reporting results from diagnostic genomic sequencing. Eur J Hum Genet 2018; 26 (01) 36-43
• 28 Kalia SS, Adelman K, Bale SJ. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19 (02) 249-255
• 29 Caulfield M, Davies J, Dennys M. et al. The 100,000 Genomes Project Protocol. 2017
• 30 Royal College of Physicians, Royal College of Pathologists. British Society for Genetic Medicine. Consent and Confidentiality in Genomic Medicine: Guidance on the Use of Genetic and Genomic Information in the Clinic. 3rd ed.. Report of the Joint Committee on Genomics in Medicine. 2019
• 31 van El CG, Cornel MC, Borry P. et al; ESHG Public and Professional Policy Committee. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2013; 21 (06) 580-584
• 32 Gomez K, Chitlur M. GEHEP panel. Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A. Thromb Haemost 2013; 109 (04) 738-743
• 33 Gouw SC, van den Berg HM, Oldenburg J. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
• 34 Johnsen JM, Fletcher SN, Huston H. et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv 2017; 1 (13) 824-834
• 35 Casini A, Blondon M, Lebreton A. et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125 (03) 553-561
• 36 Simeoni I, Stephens JC, Hu F. et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 2016; 127 (23) 2791-2803
• 37 Cortes A, Albers PK, Dendrou CA, Fugger L, McVean G. Identifying cross-disease components of genetic risk across hospital data in the UK Biobank. Nat Genet 2020; 52 (01) 126-134
• 38 Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011; 13 (01) 1-16
• 39 Gomez K, Laffan MA. Hunting for the mutation in inherited thrombophilia. Blood Coagul Fibrinolysis 2004; 15 (02) 125-127
• 40 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 41 Gomez K, Laffan M, Keeney S, Sutherland M, Curry N, Lunt P. Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctors' Organisation Good Practice Paper. Haemophilia 2019; 25 (01) 116-126